Abstract Purpose: One copy of the galanin receptor 1 (GALR1) locus on 18q is often deleted and expression is absent in some head and neck squamous cell carcinoma (HNSCC) cell lines.To determine if loss of heterozygosity and hypermethylation might silence the GALR1gene, promoter methylation status and gene expression were assessed in a large panel of HNSCC cell lines and tumors. Experimental Design: Promoter methylation of GALR1 in 72 cell lines and 100 primary tumor samples was analyzed using methylation-specific PCR. GALR1expression and methylation status were analyzed further by real-time PCR and bisulfite sequencing analysis. Results: The GALR1 promoter was fully or partially methylated in 38 of 72 (52.7%) HNSCC cell lines but not in the majority 18 of 20 (90.0%) of nonmalignant lines. GALR1 methylation was also found in 38 of 100 (38%) primary tumor specimens. Methylation correlated with decreased GALR1 expression. In tumors, methylation was significantly correlated with increased tumor size (P = 0.0036), lymph node status (P = 0.0414), tumor stage (P = 0.0037), cyclin D1 expression (P = 0.0420), and p16 methylation (P = 0.0494) and survival (P = 0.045). Bisulfite sequencing of 36 CpG sites upstream of the transcription start site revealed that CpG methylation within transcription factor binding sites correlated with complete suppression of GALR1 mRNA. Treatment with trichostatin A and 5-azacytidine restored GALR1 expression. In UM-SCC-23 cells that have total silencing of GALR1, exogenous GALR1 expression and stimulation with galanin suppressed cell proliferation. Conclusions: Frequent promoter hypermethylation, gene silencing, association with prognosis, and growth suppression after reexpression support the hypothesis that GALR1 is a tumor suppressor gene in HNSCC.
Loss of heterozygosity (LOH) on chromosome 18q in head and neck squamous cell carcinoma (HNSCC) is associated with significantly decreased survival (1) . Galanin receptor 1 (GALR1), a G-protein-coupled receptor (GPCR) that maps to the commonly lost 18q23 region (2) , exhibits aberrant expression in HNSCC cells with 18q LOH. Loss of one copy and inactivation of the remaining GALR1 gene would be consistent with it acting as a tumor suppressor gene. Abnormalities affecting GPCRs have been implicated in many human tumors (3 -5) . Similarly, there is a growing literature implicating a variety of GPCR signaling pathways in head and neck cancer (6 -14) . GALR1 and its ligand, galanin, are expressed in normal keratinocytes, suggesting that loss of GALR1 plays a role in the development or progression of HNSCC (15) . Furthermore, we found two cell lines with GALR1 mutations that affect the sixth transmembrane domain, a region known to affect GPCR function (15) .
There are three galanin receptors: GALR1, GALR2 (17q25.3), and GALR3 (22q13.1; ref. 16 ). Galanin activates the receptors and initiates signal transduction (17) . GALR1 is reported to couple to heterotrimeric G proteins of the G i type, which inhibit cyclic AMP (16) . Galanin regulates many physiologic functions in mammals (15, 18) and may have a role in Alzheimer's disease (19) . GALR2 was reported to activate G 12/13 proteins (20) that activate mitogenic cascades. However, galanin receptor function may depend on the cell type. Berger et al. (21) reported that exogenous expression of GALR2 inhibited cell proliferation and induced apoptosis in neuroblastoma cells, whereas in the same cell type expression of GALR1 only inhibited cell proliferation. Thus, the functions of GALR1, GALR2, and GALR3 are not well understood. Our recent findings support a growth regulatory function for GALR1 because antibody blockade of this receptor enhances proliferation of HNSCC cells (8) and restoration of GALR1 expression inhibits cell growth and tumor formation in HNSCC cells (22) . Thus, GALR1 appears to act as a tumor suppressor in HNSCC.
Tumor suppressor genes may be inactivated by point mutations, homozygous deletions, or LOH and aberrant methylation (23) . Methylation of CpG sites within promoter regions is often associated with silenced gene expression (24, 25) . The GALR1 promoter is a TATA-less promoter containing GC-rich sequences that may be susceptible to DNA methylation and gene silencing (26) .
In this study, we show for the first time that loss of GALR1 expression is associated with hypermethylation of key CpG sites within transcription factor binding domains and that expression can be restored after treatment with the demethylating agent, 5-azacytidine, and the histone deacetylase inhibitor, trichostatin A (TSA). Moreover, assessment of primary tumor specimens confirmed that hypermethylation is as common in patient tumors as in cell lines and is directly associated with tumor size and metastasis. Finally, restoration of GALR1 expression in HNSCC cells resulted growth inhibition in response to galanin stimulation, supporting the hypothesis that GALR1 is a tumor suppressor gene. Fig. 1 . Diagrammatic representation of the GALR1gene and its proximal promoter and GALR1methylation analysis using the MSP assay. A, GALR1exon structure and CpG sites within expanded views of the promoter region relative to the transcript start site (TSS).Vertical lines, individual CpG sites. The bracket (bottom) encloses the 260-bp region that includes theTSS and the 36 individual CpG sites that were examined for frequency of methylation. Straight arrows, relative location of the primers used for methylation-specific PCR (MSP) and bisulfite sequencing; bent arrow, TSS; arrowhead, translation start site (ATG). B, representative examples of MSP of GALR1in UM-SCC cell lines, showing samples that are fully methylated (UM-SCC-1, UM-SCC-2, and UM-SCC-23), partially methylated (UM-SCC-6, UM-SCC-10B, UM-SCC-14B, UM-SCC-22B, and UM-SCC-74B), or unmethylated (UM-SCC-10A, UM-SCC-22A, UM-SCC-56, and UM-SCC-81B 
Translational Relevance
Identifying biomarkers of those tumors that will progress and cause the death of the patient is a critical area of research, particularly if the biomarker can be linked to targeted therapy. We showed previously that loss of chromosome 18q23 was associated with poor survival in head and neck cancer and found that GALR1 mapped to the minimal region of loss.We postulated that GALR1might be a tumor suppressor gene and that loss of one GALR1copy and silencing of the other copy could promote aggressive tumor progression. In this article, we show that GALR1 promoter methylation and silencing is frequent in head and neck squamous cancers and is statistically significantly associated with decreased survival. Restoring GALR1 expression inhibits tumor cell growth. Thus, specific histone deacetylase or methyltransferase inhibitors may provide a means to target GALR1 expression in the most aggressive tumors.
Materials and Methods
Cell lines. DNA from 72 HNSCC cell lines established from patients at either the University of Michigan (62 UM-SCC) or the University of Turku (10 UT-SCC) was used for methylation-specific PCR (MSP) analysis. The letter A after the cell line number (e.g., UM-SCC-10A) designates the primary tumor cell lines. Subsequent tumor lines from the same patients have a B designation. Fibroblasts from the original tumor specimen (15 samples) or transformed B-lymphocytes from the tumor cell line donors (3 samples) were used as the source of normal somatic DNA. Nonmalignant cells from the donors of UM-SCC and UT-SCC cell lines have the same number [e.g., UM-SCC-6 and UM-6F (fibroblasts)]. Other control cells included normal human keratinocytes (NHK) and HPV16 transformed oral keratinocytes (HOK-16B) cells (a gift from Dr. No Hee Park; ref. 27) . cDNA from a normal human brain cDNA library (Invitrogen) was an additional control.
Tumor specimens. DNA was isolated from specimens obtained at surgery from 100 primary HNSCC tumors. All patients were treated at the Department of Otolaryngology, Hamamatsu University School of Medicine. Clinical information including age, sex, smoking status, tumor size, lymph node status, and stage were obtained from the clinical records. The mean age was 63.9 years (range 39-90), and the male/female ratio was 78:22. Primary tumor sites were oral cavity (n = 34), hypopharynx (n = 24), larynx (n = 20), oropharynx (n = 11), and paranasal cavity (n = 11).
Bisulfite modification. Genomic DNA was extracted using the Wizard Genomic DNA Purification Kit (Promega). Bisulfite modification of genomic DNA converts unmethylated cytidine residues to uradine residues that are then converted to thymidine during subsequent PCR (28) . Methylated cytidine residues are not altered by bisulfite treatment. In brief, 1 Ag genomic DNA was denatured with NaOH (final concentration, 0.2 mol/L) and then incubated with sodium bisulfite (3 mol/L; Sigma; pH 5.0) and hydroquinone (10 mmol/L; Sigma) at 55jC for 16 h. Bisulfite-modified DNA was purified using the Wizard DNA Clean-Up System (Promega). For DNA desulfonation, NaOH (final concentration, 0.3 mol/L) was added, incubated at room temperature for 5 min, ethanol precipitated, and resuspended in 100 AL autoclaved distilled water. Methylation analysis of the GALR1 proximal promoter. The GALR1 exon structure and the proximal promoter are shown in Fig. 1A . An expanded view of the CpG-rich proximal promoter and exon 1 extending from -362 to +773 bp that includes both the transcription start site (TSS; bent arrow) and the start codon (black arrowhead) is shown below the exon map. The 260-bp region surrounding the TSS has 36 CpG sites. Potential transcription factor binding sites were detected within this region using TFSEARCH. Sites 13 and 14 are part of a consensus activating protein-2 (Ap-2) site and site 26 is within a consensus selective promoter factor 1 (Sp1) site.
MSP analysis. Methylation in the region near the TSS was assessed using bisulfite-treated DNA PCR amplified with MSP primers, MSP-F (5 ¶-GGTTCGCGGTATTCGGTAGT-3 ¶, upstream) and MSP-R (5 ¶-TCGCCGCCCACCTCCCGACTAA-3 ¶, downstream), and unmethylated DNA-specific primers (UMSP), UMSP-F (5 ¶-GGTTTGTGGTATTTGG-TAGT-3 ¶, upstream) and UMSP-R (5 ¶-TCACCACCCACCTCCCAACTAA-3 ¶, downstream). Arrows show the binding locations of the MSP/UMSP primers below the expanded region (Fig. 1A) . The PCR conditions were 94jC for 5 min; 33 cycles at 94jC for 30 s, 60jC for 30 s, and 72jC for 40 s; and a final extension at 72jC for 5 min. The 99-bp PCR products were separated by electrophoresis through a 9% acrylamide gel and stained with ethidium bromide. To analyze the methylation status of the p16 gene and the RASSF1A gene, primers and conditions as described by Herman et al. (28) and Kuroki et al. (29) were used.
Bisulfite sequencing analysis. The frequency of methylation at 36 individual CpG sites within the bracketed 260-bp region was assessed on the top or bottom strands using bisulfite-specific sequencing. Of the 36 CpG sites analyzed, numbers 1 to 27 are upstream of the TSS and numbers 28 to 36 are downstream (Fig. 1A) . Bisulfite sequencing PCR (BSP) primer pairs specific for modified top and bottom strand DNAs were designed to contain no CpG sites. Top strand primers were BSP-U-F (5 ¶-GAGGAGGAAAGGTATTAATGGATGAGGAGG-3 ¶), BSP-U-R (5 ¶-ACTCTTTTAAAAAACTTCCTAATAATAAAT-3 ¶), and BSP-U-RN (5 ¶-AATACCAAAAACTTCTCTACTACAACTAA-3 ¶). In a second PCR, BSP-U-F and a nested primer, BSP-U-RN, were used with 0.5 AL of the PCR product as template. PCR conditions for both first and second PCR were 94jC for 5 min; 35 cycles at 94jC for 30 s, 50.8jC for 30 s, and 72jC for 50 s; and a final extension at 72jC for 7 min. The bottom strand primers were BSP-L-F (5 ¶-AGGTTTTTTGGTGGTGGATA-3 ¶) and BSP-L-R (5 ¶-ACCAATTTTACAAAACTCCA-3 ¶). The binding locations of the bisulfite sequencing primers are shown by arrows below the expanded region (Fig. 1A) . The bottom strand PCR conditions were 94jC for 5 min; 40 cycles at 94jC for 30 s, 56.0jC for 30 s, and 72jC for 50 s; and a final extension at 72jC for 5 min. The PCR products were separated by electrophoresis through a 1.5% agarose gel containing ethidium bromide, extracted from the gel with the QIAquick Gel Extraction Kit (Qiagen), and cloned into pGEN T-Easy vector, and at least nine clones were sequenced by the ABI model 3730 sequencer using T7 or SP6 primers.
RNA extraction and GALR1 reverse transcription-PCR. Total RNA from 13 HNSCC cell lines, including 9 with loss of one copy of chromosome 18q, 1 with no loss of 18q, and 3 for which 18q status is unknown, was isolated using the RNeasy Mini Kit (Qiagen). After DNase treatment, cDNA was generated using an oligo(dT) 16 primer with SuperScript II reverse transcriptase (Invitrogen). Primer sequences for amplifying the coding region of the human GALR1 cDNA (GenBank accession no. AY541036) are as follows: RT-GALR1-sense 5 ¶-CACTTGCATAAAAAGTTGAAG-3 ¶ (location in coding sequence; 676-696) and RT-GALR1 -antisense 5 ¶-TTATCACACATGAGTA-CAATTGG-3 ¶ (1,053-1,031; ref. 30) . The PCR product size was 378 bp. The PCR conditions were 94jC for 8 min; either 40 or 45 cycles at 94jC for 30 s, 52.0jC for 30 s, and 72jC for 45 s; and a final extension at 72jC for 8 min. Primers for the GAPDH gene were described previously (30) .
Quantitative reverse transcription-PCR for GALR1. Quantitative PCR was done with the ABI PRISM 7700 HT Sequence Detection System (Applied Biosystems). Inventoried Assays-on-Demand Gene Expression Products (Applied Biosystems), which passed quality-control manufacturer's specifications, were used as primers and probe (Hs00175668_m1). The cDNA was generated from DNase-treated total RNA using Random primers (Invitrogen) with SuperScript II reverse transcriptase (Invitrogen). For each PCR evaluation, 10 AL diluted cDNA, 12.5 AL TaqMan Universal PCR Master Mix (Applied Biosystems), and 1.25 AL Assay Mix were added to a final volume of 25 AL. The thermal cycler conditions were as follows: 1 cycle of preheating at 50jC for 2 min and AmpliTaq Gold activation at 95jC for 10 min followed by 50 cycles of denaturing at 95jC for 15 s and annealing/ extension at 60jC for 60 s. Analysis was done with ABI Prism Sequence Detection System v1.7a software (Applied Biosystems) following the manufacturer's instructions. For comparisons between samples, the mRNA expression of the target genes was normalized to GAPDH mRNA expression.
Immunohistochemistry. Tumor sections (5 Am) were dewaxed with xylene, hydrated through graded alcohols, and rehydrated in water. Sections were microwaved in citrate buffer (pH 6.0) three times for 5 min, and endogenous peroxidase activity was blocked using 0.5% hydrogen peroxide in methanol for 30 min. After a 20% goat serum was applied to the sections for 10 min, they were incubated with monoclonal antibodies against cyclin D1 protein (1:100, 5D4; IBL), (31) .
Reactivation of GALR1 expression. Twelve hours after plating, cultures were incubated either for 48 h with 5-azacytidine (15 and 30 Ag/mL; Sigma), an inhibitor of DNA methyltransferase, for 24 h with 300 nmol/L TSA (Sigma), an inhibitor of histone deacetylase, or for 48 h with 5-azacytidine followed by 24 h with TSA. The medium was then removed and cultures were maintained in standard DMEM, which was replaced every other day for 2 to 5 days. Transcripts were optimal on day 4 or 5 (32, 33) .
Transient transfection, Western blotting, and cell proliferation assay. UM-SCC-23, a cell line established from a human laryngeal squamous cell carcinoma, was cultured in DMEM (Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum at 37jC in 5% CO 2 . The GALR1 sequence was obtained from a human cDNA library (Invitrogen), COOH-terminal HA-tagged, and subcloned into the pcDNA3 vector (Invitrogen) containing an internal ribosomal entry site (Ires) and green fluorescent protein (GFP) sequence. The pCMVIresGFP vector was used as a transfection control. The UM-SCC-23-GALR1 and UM-SCC-23-mock cells were established by transfecting with pCMVGALR1HAIresGFP or pCMVIresGFP respectively using LipofectAMINE (Invitrogen) followed by selection for GFP-positive cells. Twenty-four hours after plating, stably transfected cells were fed with serum-free medium containing 0.1% bovine serum albumin for 24 h to induce quiescence. Then, 1 Amol/L galanin (Anaspec) was added. Cell proliferation was measured by counting cells with a Coulter counter model Z1 (Beckman Coulter). Cells were lysed with 0.1% NP-40 lysis buffer containing protease (Calbiochem) and phosphatase (Sigma) inhibitor cocktails. To avoid protein aggregation, cells lysates were treated with 1,000 units N-glycosidase F or a mock digestion without the enzyme (mock; New England Biolabs) and subjected to electrophoresis without boiling. Equal amounts of protein were electrophoresed on 10% SDS-PAGE gels and transferred to Hybond-P (Amersham Biosciences). The mouse monoclonal anti-HA tag antibody (Convance) was used to detect exogenous GALR1. GAPDH was detected by mouse monoclonal anti-GAPDH (Chemicom International) as an internal control for protein loading. The membranes were incubated overnight with primary antibody at 4jC followed by incubation with horseradish peroxidase-conjugated rabbit anti-mouse secondary antibody (Amersham Biosciences).
Statistical analysis. The association between discrete variables and GALR1 methylation was tested by the Fisher's exact probability test or the Mann-Whitney U test. In the colony formation assay, comparisons and tests for statistical significance were made by Student's t test. The 5-year overall survival rates were constructed using the method of Kaplan-Meier and analyzed by the log-rank test. Cox's proportional hazards regression analysis, which involved age, tumor site, smoking status, stage grouping, cyclin D1 expression, and GALR1 methylation, was used to identify the multivariate predictive value of the prognostic factors. A significant difference was identified when the probability was <0.05.
Results

MSP.
To determine if the GALR1 promoter is affected by methylation in HNSCC, MSP analysis was carried out on bisulfite-treated DNA from 72 UM-SCC and UT-SCC cell lines as well as from fibroblast, EBV-transformed B lymphocyte, and normal keratinocyte samples. In addition, we analyzed bisulfite-treated DNA from primary tumors of 100 HNSCC patients in the Hamamatsu University Pathology archives. Forward primers for MSP and UMSP bind in the segment of the promoter that contains CpG dinucleotides 13 to 15, which correspond to a consensus Ap-2 site. Reverse primers for MSP and UMSP anneal to the segment that includes CpG dinucleotides 25 to 27, which correspond to a consensus Sp1 site (Fig. 1A) . These sites are immediately upstream of the TSS. Examples of the methylated and unmethylated PCR products from a representative subset of the cell lines are shown in Fig. 1B and the results from all cell lines are summarized in Table 1 . The subset included nine cell lines (UM-SCC-2, UM-SCC-10A, UM-SCC-10B, UM-SCC-14B, UM-SCC-22A, UM-SCC-22B, UM-SCC-23, UM-SCC-54, and UM-SCC-81B) shown previously to have LOH affecting the GALR1 locus, one with no 18q loss (UM-SCC-74B), and three (UM-SCC-1, UM-SCC-6, and UM-SCC-56) that were not tested for 18q loss. In three cell lines (UM-SCC-1, UM-SCC-2, and UM-SCC-23), only methylated Research.
on July 17, 2017. © 2008 American Association for Cancer clincancerres.aacrjournals.org Downloaded from alleles were detected (Fig. 1B) . Five other cell lines (UM-SCC-10B, UM-SCC-14B, UM-SCC-22B, UM-SCC-54, and UM-SCC-74B) had predominantly methylated alleles. In contrast, UM-SCC-81B, UM-SCC-10A, and UM-SCC-22A had only unmethylated alleles (Fig. 1B) . Of interest, GALR1 is mostly unmethylated in UM-SCC-10A and UM-SCC-22A, whereas GALR1 is methylated in UM-SCC-10B and UM-SCC-22B that came from a recurrent and metastatic tumor, respectively. Among 72 UM-SCC and UT-SCC cell lines tested, the GALR1 promoter was hypermethylated in 14 of 72 (19.4%) cases, partially methylated in 24 (33.3%), and unmethylated in 34 (47.2%). In contrast, 18 of 20 (90.0%) of the nonmalignant samples were unmethylated and only 2 (10.0%) were partially methylated (Supplementary Table S1 ). For comparison, we also assessed the methylation status of p16 and RASSF1A, two tumor suppressor genes that are frequently reported to be silenced by methylation. As shown in Supplementary Table S1 , like GALR1, p16 was fully or partially methylated in 38% of the tumors and RASSF1A in 30%. Among DNA samples from 100 previously untreated primary tumors tested with the same primers (Fig. 1C) , the GALR1 promoter was methylated in 38 of 100 (38.0%) cases and unmethylated in 62 (62.0%). Methylation of GALR1 significantly correlated with increased tumor size (P = 0.0036), lymph node status (P = 0.0414), tumor stage (P = 0.0037), increased cyclin D1 expression (P = 0.0420), p16 methylation (P = 0.0494), and overall 5-year survival (P = 0.0448; Table 1 ). There was no association with expression of p53, PTEN, or RASSAF1. In multivariate analysis, taking into account age, tumor site, smoking, tumor stage, and cyclin D1 expression, only GALR1 methylation and stage were significant predictors of poor survival (Table 2) .
GALR1 expression in 13 UM-SCC cell lines tested for promoter methylation. The 13 UM-SCC cell lines shown in Fig. 1 were tested for GALR1 expression using reverse transcription-PCR (RT-PCR) with either 40 or 45 cycles of PCR. Absence of GALR1 expression corresponded well with the methylation status shown in Fig. 1 . Three cell lines (UM-SCC-1, UM-SCC-2, and UM-SCC-23) had no detectable GALR1 mRNA even after 45 cycles as determined by absence of PCR product with this stringent test for message ( Fig. 2A, top) . cDNA from normal fibroblasts and brain were GALR1 positive (Fig. 2B) , which is consistent with GALR1 expression in normal cells.
GALR1 expression after 5-azacytidine and TSA treatment. If DNA methylation and the associated deacetylation of histones that frequently accompanies methylation is responsible for silencing GALR1 gene expression, it should be possible to reexpress the gene by reversing the epigenetic effects. We treated the three completely silenced cell lines (UM-SCC-1, UM-SCC-2, and UM-SCC-23) with methyltransferase (5-azacytidine) and/or histone deacetylase (TSA) inhibitors. In UM-SCC-1 and UM-SCC-23, either 5-azacytidine or TSA was sufficient to induce GALR1 expression. For UM-SCC-2, only slight GALR1 expression was observed when TSA was used alone. Given alone, 5-azacytidine induced some expression; however, when both drugs were used together GALR1 expression was more robust. Thus, all three cell lines exhibited restored GALR1 expression after inhibition of methyltransferase and histone deacetylase (Fig. 2C) .
Bisulfite sequencing analysis. To examine the methylation of individual alleles and their association with GALR1 silencing, we focused on the 36 CpG sites surrounding the TSS (Fig. 1A) using BSP with the BSP primers for the top (BSP-U-F/BSP-U-RN/BSP-U-R) and bottom (BSP-L-F/BSP-L-R) DNA strands (as shown in Fig. 1A ). We sequenced nine or more clones from the top and bottom strands of the DNA from 13 cell lines representing hypermethylated, partially methylated, or unmethylated examples. The percentage of methylated alleles for each of the 36 CpG sites is shown in Fig. 3A (top strand) and Fig. 3B (bottom strand) for the 13 HNSCC cell lines.
Methylation status of transcription factor binding sites. CpG sites 13 and 14 (top strand: 5 ¶-GCCCGCGGC-3 ¶ and bottom strand: 5 ¶-GCCGCGGGC-3 ¶) are within a near-perfect consensus AP-2 transcription factor binding site upstream of the TSS. DNA methylation within AP-2 binding sites is known to decrease the affinity of AP-2 binding (34) . CpG site 26 is located within a consensus Sp1 binding site (top strand: 5 ¶-GGGCGG-3 ¶ and bottom strand: 5 ¶-CCGCCC-3 ¶). Transcription factor binding to Sp1 sites is also known to be significantly decreased by methylation of the first two cytosines on the bottom strand of the Sp1 recognition sequence (bottom strand: 5 ¶-CCGCCC-3 ¶; ref. 35) . The frequency of methylated alleles corresponded to the MSP/UMSP results in Fig. 1 and with the amplification of message shown in Fig. 2 .
Quantitative RT-PCR for GALR1. To quantify message expression in relation to promoter methylation generally and the transcription factor binding sites, real-time RT-PCR was used. The three GALR1-negative cell lines, UM-SCC-1, UM-SCC-2, and UM-SCC-23, are methylated on 100% of CpG sites 13, 14, and 26, with only two exceptions: UM-SCC-1 at site 14 (bottom strand) had 91% methylated alleles and UM-SCC-2 at site 13 (top strand) had 93% methylated alleles. A high proportion of these alleles are also heavily methylated in UM-SCC-10B, UM-SCC-14B, UM-SCC-22B, UM-SCC-54, and UM-SCC-74B, cell lines with barely detectable GALR1 message. In contrast, for the cell lines with more readily detectable message, the proportion of heavily methylated alleles falls below 50% and the level of methylation at sites 13, 14, or 26 ( Fig. 3A and B ) also falls sharply with increasing message expression (Fig. 3C) . In fact, in cell lines with readily detectable GALR1 message expression, CpG sites 13 to 15 and 25 to 27 usually have only moderate methylation when compared with the nonexpressing hypermethylated cell lines. No GALR1 message could be detected by quantitative PCR in cell lines UM-SCC-1, UM-SCC-2, and UM-SCC-23 (DDCT value: 0.029 + 0.031, 0.001 + 0.001, and 0.003 + 0.009; Fig. 3C ). The average of the methylated alleles on the top and bottom strands in these cells lines was 94.8%, 95.0%, and 95.4%, respectively ( Fig. 3A and B) . UM-SCC-10B, UM-SCC-14B, UM-SCC-22B, UM-SCC-54, and UM-SCC-74B had barely detectable expression of GALR1 by quantitative PCR (DDCT value: 0.051 + 0.023 to 0.182 + 0.023) and had a high proportion of methylated sites (averages: 88.8-92.7%). UM-SCC-6, UM-SCC-10A, UM-SCC-22A, UM-SCC-56, and UM-SCC-81B, which express GALR1 expression by RT-PCR and quantitative PCR (DDCT value: 0.291 + 0.06 to 5.278 + 0.418), exhibited a range of methylation levels ranging from 2.8% to 43.2% of sequenced sites. Thus, promoter methylation showed considerable variability but was consistent with mRNA expression levels (Fig. 3C) . To determine if GALR1 methylation in tumor specimens also was associated with gene silencing, we isolated mRNA from frozen tissue. GALR1 expression analyzed by quantitative RT-PCR (Fig. 3D) showed that six tumors H-27, (Fig. 1C) exhibited little or no mRNA expression. In contrast, 3 of 6 (H-88, H-96, and H-97) tumors without GALR1 promoter methylation (Fig. 1C) exhibited relatively robust mRNA expression (Fig. 3D) .
Suppression of cell growth after restoration of GALR1 expression. UM-SCC-23 cell line, which exhibits extensive hypermethylation and expresses no GALR1 message, was used for assessment of exogenous GALR1 reexpression and effects on cell proliferation in response to galanin stimulation. UM-SCC-23 cells transfected with wild-type GALR1 in the pCMVIresGFP or pCMVGALR1HAIresGFP constructs were assessed for GALR1 expression in Western blot using antibody specific for the HA tag (Fig. 4A) . Treatment with 1 Amol/L galanin suppressed cell proliferation in UM-SCC-23GALR1HA cells by 24% (P = 0.0054) relative to the vector alone transfected cells (Fig. 1C) Research.
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Discussion
Genetic analysis of HNSCC has revealed LOH at 3p, 8p, 9p, 11q, 13q, and 18q alleles in a significant fraction of tumors (36) . 18q LOH is linked to advanced stage and poor survival in HNSCC, suggesting that one or more genes on this chromosome are important in tumor behavior (1) . The commonly lost region of 18q is 18q23, which was lost in 53% (D18S461) to 75% (D18S70), including the GALR1 locus (37) . Galanin and its receptors are variably expressed in HNSCC (15) .
GALR1 is a GPCR. GPCRs with the typical seven-transmembrane spanning domains and their ligands are involved in regulation of cellular physiology and complex behaviors mediated through numerous signal transduction and integration pathways (17, 38) . We showed recently that, in HNSCC, galanin and GALR1 signal via extracellular signal-regulated kinase 1/2 activation to inhibit expression of cyclin D1, upregulate expression of the cyclin-dependent kinase inhibitors p27 kip1 and p57 kip2 , and inhibit tumor cell proliferation and tumor growth (22) . These findings support the concept that GALR1 regulates cell growth and functions as a tumor suppressor gene.
Some tumor suppressor genes exhibit homozygous loss, but in our studies of LOH, we found no examples of homozygous loss of the GALR1 locus. Therefore, we suspected that an epigenetic mechanism of gene silencing might be at work. In this study, we show that GALR1 expression is frequently absent in HNSCC. Furthermore, expression-negative squamous cancers and cell lines exhibit hypermethylation of CpG islands in the GALR1 promoter region. In a survey of 62 UM-SCC and 10 UT-SCC cell lines using GALR1 promoter MSP, we showed that 14 of 72 (19.4%) were completely methylated and another 24 of 72 (33.3%) were partially methylated. Thus, more than half of the cell lines (52.7%) exhibit evidence of GALR1 epigenetic silencing. The frequency of promoter methylation of p16 22 of 72 (30.6%) and RASSF1A 10 of 72 (13.9%), two other tumor suppressor genes, was similar to that of GALR1 in the UM-SCC and UT-SCC cell lines. Hypermethylation of the GALR1 promoter was also found in a similar proportion (38%) of primary head and neck tumor specimens, and suppression of GALR1 expression correlated with promoter methylation. Thus, GALR1 resembles other major tumor suppressor genes in frequency of aberrant promoter methylation both in vitro and in vivo. Importantly, there is a significant correlation between GALR1 promoter methylation and tumor size, lymph node status, tumor stage, cyclin D1 expression, and p16 methylation status in primary samples. Moreover, in multivariate analysis, only GALR1 methylation and clinical stage were significantly associated with poor survival when age, smoking status, tumor site, and cyclin D1 expression were also considered. This is consistent with our earlier findings that LOH of the GALR1 locus on 18q is associated with poor prognosis (1). Many lines with LOH had little or no GALR1 expression, which is consistent with loss of one allele and silencing of the other. We did find strong GALR1 expression in UM-SCC-74A, a cell line with no LOH. Of interest, LOH was present in primary tumor cell lines from two patients, UM-SCC-10A and UM-SCC-22A, but methylation was low or absent and GALR1 expression was still detectable. However, in the recurrent or metastatic tumor cell lines from these same donors, UM-SCC-10B and UM-SCC-22B, the methylation signal was potent, suggesting that silencing of the remaining allele occurred with progression. The significant association of increased cyclin D1 expression with GALR1 methylation in these tumors is consistent with our previous in vitro study (22) that showed that GALR1 and galanin down-regulate cyclin D1 expression. Thus, loss of GALR1 expression appears to be linked to loss of control of cyclin D1 expression, which is consistent with tumor progression.
The MSP assay is a convenient and sensitive method to examine promoter methylation status, and in this study, it was fully concordant with mRNA expression. It became clear that although these cell lines have a strong promoter methylation signal, a critical feature in complete suppression of mRNA expression is whether the transcription factor binding sites are hypermethylated. Thus, the choice of the correct primer sets is an essential element for an effective MSP assay and should be designed based on bisulfite-treated DNA sequencing and mRNA expression (39, 40) as we did in the current study. The MSP and UMSP each included three CpG sites, which spanned at least two transcription factor binding sites. AP-2 is a cell type-specific transcription factor expressed in neural crest and ectoderm-derived tissues, including craniofacial, skin, and urogenital tissues. Although footprinting has shown some promiscuity in AP-2 sites, AP-2 protein homodimers bind consistently to a consensus palindromic sequence, 5 ¶-GCCNNNGGC-3 ¶. In the GALR1 promoter, this sequence includes CpG sites 13 and 14 (41, 42) . AP-2 has roles in both normal development and development/progression of cancer (42) . Methylation at CpGs within the AP-2-binding site distinguish the UM-SCC cell lines (such as UM-SCC-1, UM-SCC-2, and UM-SCC-23) that fail to express GALR1 mRNA from those such as UM-SCC-14B and UM-SCC-74B that do express GALR1. This is consistent with reports indicating that methylation of AP-2 CpG sites inhibits AP-2 binding and suppresses AP-2-regulated transcription of genes such as SOD2, E-cadherin, and the proenkephalin-CAT gene (34, 43, 44) . Sp1 sites are found in the promoter region of many housekeeping genes, indicating a role for the Sp1 as a basal transcription factor (45) . Some reports indicate that methylation at Sp1 binding sites has no influence on Sp1 binding (35, 46) , whereas others (28) used electrophoretic mobility shift assays to show that Sp1 binding to the Rb promoter can be abolished when the first two cytosines on the bottom strand (5 ¶-CCGCCC-3 ¶) are methylated (34) . Similarly, the MBD1 and MCAF complex blocks transcription by affecting Sp1 in heavily methylated promoter regions (47) . MCAF physically binds Sp1 and the general transcription apparatus like a positive regulator. MBD1-MCAF seems to interfere with Sp1-mediated activation of the transcription preinitiation complexes in methylated DNA regions (47) . The methyl groups on DNA could interfere with binding of specific transcription factors and have been described as a mechanism for transcriptional inactivation of tumor suppressor genes in subsets of primary cancers. Within the CpG islands, there is typically a core promoter and a TSS and gene expression is completely repressed when this region becomes hypermethylated (48) . Our results show that the methylation levels of CpG sites 13 and 14, on the top strand in the AP-2 binding site, strongly influence the expression of GALR1 mRNA. In addition, it is likely that heavy methylation of the promoter region also causes inhibition of Sp1 binding and repression of GALR1 mRNA expression.
Furthermore, in 3 of 3 HNSCC cell lines that do not express any detectable GALR1 mRNA, the gene could be reactivated by treatment with 5-azacytidine alone, TSA alone, and/or the combination of 5-azacytidine and TSA. Reactivation of heavily methylated cell lines with histone deacetylase inhibitors alone is somewhat unusual and indicates that chromatin silencing effects can be reversed even in the presence of DNA methylation. This also suggests that the combination of methylation and deacetylation act together to silence expression and that variability in DNA acetylation may account for some of the heterogeneity we observed in expression of GALR1 in lines with relatively strong methylation signals. Our data show that in HNSCC promoter hypermethylation of GALR1 is associated with loss of gene expression that can be reversed by treatment with methyltransferase and histone deacetylase inhibitors.
Our results are consistent with the hypothesis that GALR1 is a probable tumor suppressor gene in HNSCC. We show for the first time that expression of GALR1 mRNA is lost in HNSCC as a consequence of DNA methylation. Furthermore, silencing of the GALR1 gene by methylation may be a critical event in tumor progression of HNSCC, because 18q LOH is associated with tumor progression (36) , and in this study, GALR1 promoter methylation was observed to be greater in cell lines derived from secondary tumors in the same patient (e.g., UM-SCC-10A has a weaker MSP signal than UM-SCC-10B), and the same occurs in UM-SCC-22A and UM-SCC-22B. Furthermore, GALR1 promoter methylation was associated with larger primary tumor size, clinical stage, lymph node metastasis, cyclin D1 expression and p16 methylation, and poorer survival. In this article, we have shown that transcriptional repression is likely mediated by inhibition of AP-2 and Sp1 binding secondary to methylation of critical CpGs in the GALR1 promoter. Furthermore, reexpression of GALR1 in transfected cells results in galanin-induced inhibition of cell proliferation. Finally, GALR1 can be reactivated by altering chromatin modifications with methyltransferase and histone deacetylase inhibitors, raising the promise of selective small-molecule inhibitors of these enzymes as potential therapeutic agents in HNSCC.
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